Dr. Reddy's Laboratories (RDY) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Dr. Reddy's Laboratories (RDY) is Neutral.

The composite score behind that read is +0.15, weighing +0.51 of bullish evidence against -0.40 bearish.

Dr. Reddy's Laboratories last closed at $12.48, +2.30% on the session.

Against the IVW growth benchmark the position is +1.50% over the forecast window.

The read is built from 15 underlying insights — 8 bullish and 7 bearish.

Agreement across those insights is 53%.

19 graded predictions for RDY so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Dr. Reddy's Laboratories in the 30th percentile on valuation and the 56th percentile on return on equity, where 100 is best.

Dr. Reddy's Laboratories is classified under Health Care / Pharmaceuticals, with a market capitalisation of $10.16B.

StockMap tracks Dr. Reddy's Laboratories as the 19th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Dr. Reddy's Laboratories ranks 24th of 151 in the group, against a group median of -0.08.